BioInvent International AB (publ) (STO:BINV)
Sweden · Delayed Price · Currency is SEK 4.300
-1.130 (-20.81%)
Nov 2, 2026, 5:29 PM CET
STO:BINV Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 39.98 | 226.5 | 44.69 | 71.46 | 326.13 | 19.38 | |
Revenue Growth | -83.67% | 406.86% | -37.47% | -78.09% | 1582.45% | -86.85% |
Gross Profit | 39.98 | 226.5 | 44.69 | 71.46 | 326.13 | 19.38 |
Selling, General & Admin | 70.18 | 73.67 | 58.3 | 51.61 | 50.75 | 39.44 |
Research & Development | 466.01 | 504.22 | 457.73 | 390.43 | 325.93 | 258.34 |
Other Operating Expenses | 0.03 | -0.12 | -0.1 | -0.02 | -0.08 | -0.23 |
Operating Expenses | 536.22 | 577.77 | 515.93 | 442.02 | 376.6 | 297.55 |
Operating Income | -496.24 | -351.28 | -471.25 | -370.56 | -50.47 | -278.17 |
Interest Expense | -0.4 | -0.4 | -0.56 | -0.64 | -0.65 | -0.52 |
Interest & Investment Income | 10.87 | 19.87 | 42.09 | 40.61 | 9.07 | 0.26 |
Currency Exchange Gain (Loss) | -0.65 | -0.65 | 0.47 | 0.49 | -0.45 | -0.03 |
EBT Excluding Unusual Items | -486.43 | -332.46 | -429.24 | -330.1 | -42.5 | -278.44 |
Pretax Income | -486.43 | -332.46 | -429.24 | -330.1 | -42.5 | -278.44 |
Income Tax Expense | 0.42 | 0.4 | 0.14 | 0.2 | - | - |
Net Income | -486.85 | -332.86 | -429.38 | -330.3 | -42.5 | -278.44 |
Net Income to Common | -486.85 | -332.86 | -429.38 | -330.3 | -42.5 | -278.44 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 66 | 66 | 66 | 66 | 62 | 54 |
Shares Outstanding (Diluted) | 66 | 66 | 66 | 66 | 62 | 54 |
Shares Change | 0.10% | - | 0.06% | 6.90% | 13.59% | 88.61% |
EPS (Basic) | -7.40 | -5.06 | -6.53 | -5.02 | -0.69 | -5.14 |
EPS (Diluted) | -7.40 | -5.06 | -6.53 | -5.02 | -0.69 | -5.14 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -451.58 | -255.02 | -390.5 | -355 | -53.6 | -259.1 |
Free Cash Flow Per Share | -6.86 | -3.88 | -5.93 | -5.40 | -0.87 | -4.78 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -1241.16% | -155.09% | -1054.58% | -518.54% | -15.48% | -1435.02% |
Profit Margin | -1217.66% | -146.96% | -960.87% | -462.22% | -13.03% | -1436.46% |
Free Cash Flow Margin | -1129.45% | -112.59% | -873.88% | -496.77% | -16.44% | -1336.68% |
EBITDA | -486.3 | -339.58 | -460.01 | -361.29 | -41.91 | -269.79 |
EBITDA Margin | - | -149.93% | - | - | -12.85% | - |
D&A For EBITDA | 9.94 | 11.69 | 11.24 | 9.26 | 8.56 | 8.37 |
EBIT | -496.24 | -351.28 | -471.25 | -370.56 | -50.47 | -278.17 |
EBIT Margin | - | -155.09% | - | - | -15.48% | - |